Template:ACCP VTE treatment guidelines/2012
Jump to navigation
Jump to search
ACCP Antithrombotic therapy for VTE (2012, adapted):[1]
- In patients with PE and no cancer, recommend VKA over LMWH for long-term therapy (Grade 2C).
- In patients with PE and no cancer who are not treated with VKA, recommend LMWH over dabigatran or rivaroxaban for long-term therapy (Grade 2C).
- In patients with PE and cancer, recommend LMWH over VKA (Grade 2B).
- In patients with PE and cancer who are not treated with LMWH, recommend VKA over dabigatran or rivaroxaban for long-term therapy (Grade 2C).